| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
149,990,000 |
| Market
Cap: |
137.98(M) |
| Last
Volume: |
394,168 |
Avg
Vol: |
182,850 |
| 52
Week Range: |
$0.9199 - $0.9199 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lineage Cell Therapeutics is a clinical-stage biotechnology company developing cell therapies. Co. has several allogeneic cell therapy programs in development: OpRegen®, a retinal pigment epithelium cell replacement therapy for the treatment of advanced dry age-related macular degeneration with geographic atrophy; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injuries; VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells; and other product candidates in preclinical development covering a range of therapeutic areas and target tissues or organs. Co. has rights to HyStem, a patented biomaterial that mimics naturally occurring extracellular matrix.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
96,155 |
6,836,925 |
6,836,925 |
6,836,925 |
| Total Buy Value |
$100,001 |
$7,110,902 |
$7,110,902 |
$7,110,902 |
| Total People Bought |
1 |
3 |
3 |
3 |
| Total Buy Transactions |
1 |
4 |
4 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bradsher Neal C |
Director |
– • • |
2019-04-16 |
4 |
A |
$1.32 |
$332,397 |
D/D |
251,835 |
33,980,826 |
|
- |
|
| Hogge Gary S. |
SVP,Clinical & Medical Affairs |
• – – |
2019-03-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
28,445 |
|
- |
|
| Mulroy Michael H. |
Director |
– • – |
2019-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
194,271 |
226,821 |
|
- |
|
| Kingsley Alfred D |
Director |
– • – |
2019-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
6,390 |
5,457,945 |
|
- |
|
| Bailey Don M |
Director |
– • – |
2019-03-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
62,647 |
|
- |
|
| Bradsher Neal C |
Director |
– • • |
2019-03-08 |
4 |
A |
$0.00 |
$0 |
I/I |
0 |
33,728,991 |
|
- |
|
| Bradsher Neal C |
Director |
– • • |
2019-03-08 |
4 |
A |
$0.00 |
$0 |
D/D |
3,757,430 |
33,728,991 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2019-01-01 |
4 |
D |
$0.91 |
$37,323 |
D/D |
(40,880) |
59,120 |
|
- |
|
| Culley Brian M |
President and CEO |
• • – |
2019-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
100,000 |
100,000 |
|
- |
|
| Skibsted Russell |
Chief Financial Officer |
• – – |
2018-12-18 |
4 |
D |
$1.03 |
$8,014 |
D/D |
(7,781) |
24,078 |
|
- |
|
| Skibsted Russell |
Chief Financial Officer |
• – – |
2018-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
22,500 |
31,859 |
|
- |
|
| Patton Stephana Eilene |
General Counsel & Secretary |
• – – |
2018-12-18 |
4 |
D |
$1.03 |
$9,795 |
D/D |
(9,510) |
34,485 |
|
- |
|
| Patton Stephana Eilene |
General Counsel & Secretary |
• – – |
2018-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,500 |
43,995 |
|
- |
|
| Skibsted Russell |
Chief Financial Officer |
• – – |
2018-10-04 |
4 |
D |
$2.22 |
$8,638 |
D/D |
(3,891) |
9,359 |
|
- |
|
| Skibsted Russell |
Chief Financial Officer |
• – – |
2018-10-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,250 |
13,250 |
|
- |
|
| Patton Stephana Eilene |
General Counsel & Secretary |
• – – |
2018-10-04 |
4 |
D |
$2.22 |
$10,556 |
D/D |
(4,755) |
16,495 |
|
- |
|
| Patton Stephana Eilene |
General Counsel & Secretary |
• – – |
2018-10-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,750 |
21,250 |
|
- |
|
| West Michael D |
Co-Chief Executive Officer |
• • – |
2018-09-17 |
4 |
D |
$2.31 |
$8,739 |
D/D |
(3,783) |
893,913 |
|
- |
|
| West Michael D |
Co-Chief Executive Officer |
• • – |
2018-09-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,938 |
897,696 |
|
- |
|
| Andrews Deborah J |
Director |
– • – |
2018-09-11 |
4 |
B |
$2.35 |
$3,769 |
D/D |
1,604 |
10,000 |
2.31 |
- |
|
| Mohanty Aditya P. |
Co-Chief Executive Officer |
• • – |
2018-07-10 |
4 |
D |
$2.20 |
$3,566 |
D/D |
(1,621) |
101,384 |
|
- |
|
| Mohanty Aditya P. |
Co-Chief Executive Officer |
• • – |
2018-07-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,687 |
103,005 |
|
- |
|
| West Michael D |
Co-Chief Executive Officer |
• • – |
2018-07-10 |
4 |
D |
$2.20 |
$1,190 |
D/D |
(541) |
886,758 |
|
- |
|
| West Michael D |
Co-Chief Executive Officer |
• • – |
2018-07-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,562 |
887,299 |
|
- |
|
| West Michael D |
Co-Chief Executive Officer |
• • – |
2018-04-10 |
4 |
D |
$2.49 |
$1,347 |
D/D |
(541) |
885,737 |
|
- |
|
194 Records found
|
|
Page 4 of 8 |
|
|
